COMPLETEDPhase 4

Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment

The study is designed to answer the following questions: 1. What is the levels of visceral adiposity index and Triglycerides/HDL cholesterol ratio in hypogonadism? 2. What is the effect of testosterone replacement on the visceral adiposity index and Triglycerides/HDL cholesterol ratio?

Sponsor

Gulhane School of Medicine

Enrollment

150 participants

Sites

1 locations

Start Date

July 2013

Completion

April 2014

HypogonadismTestosterone

Enrollment & Timeline

Completed

Target N

150

participants

Sites

locations

Duration

9 months

total trial span

Rate

pts/month needed

At 1 sites, each site needs to enroll approximately 17.0 patients/month to hit the enrollment target on schedule.

View on ClinicalTrials.gov

Ask AI

Primary Outcomes

time to change of visceral adiposity index with testosteron replacement

baseline and 6 months

time to change of TG/HDL cholesterol ratio with testosteron replacement

baseline and 6 months

Ask AI

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

No linked publications found in PubMed

PubMed/NCBI (daily updates) FDA FAERS (quarterly updates) WHO ICTRP (weekly updates)

Ask AI

Fetching protocol from ClinicalTrials.gov…

COMPLETEDPhase 4

Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment

Sponsor

Gulhane School of Medicine

Enrollment

150 participants

Sites

1 locations

Start Date

July 2013

Completion

April 2014

HypogonadismTestosterone

Enrollment & Timeline

Completed

Target N

150

participants

Sites

locations

Duration

9 months

total trial span

Rate

pts/month needed

At 1 sites, each site needs to enroll approximately 17.0 patients/month to hit the enrollment target on schedule.

View on ClinicalTrials.gov

Ask AI

Primary Outcomes

time to change of visceral adiposity index with testosteron replacement

baseline and 6 months

time to change of TG/HDL cholesterol ratio with testosteron replacement

baseline and 6 months

Ask AI

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

No linked publications found in PubMed

PubMed/NCBI (daily updates) FDA FAERS (quarterly updates) WHO ICTRP (weekly updates)

Ask AI

Eligibility

Min Age

18 Years

Max Age

26 Years

Sex

male

Healthy Volunteers

Yes

View full criteria

Inclusion Criteria:

* Men
* Congenital hypogonadism
* Treatment Naive

Exclusion Criteria:

* Previous history of androgen replacement
* Hypertension
* Diabetes mellitus

Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment

Enrollment & Timeline

Primary Outcomes

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment

Enrollment & Timeline

Primary Outcomes

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

Eligibility

Trial Sites (1)